7 6 3 l e t t e r S Zika virus (ZIKV) infection of pregnant women can cause a wide range of congenital abnormalities, including microcephaly, in the infant, a condition now collectively known as congenital ZIKV syndrome 1 . A vaccine to prevent or significantly attenuate viremia in pregnant women who are residents of or travelers to epidemic or endemic regions is needed to avert congenital ZIKV syndrome, and might also help to suppress epidemic transmission. Here we report on a live-attenuated vaccine candidate that contains a 10-nucleotide deletion in the 3′ untranslated region of the ZIKV genome (10-del ZIKV). The 10-del ZIKV is highly attenuated, immunogenic, and protective in type 1 interferon receptor-deficient A129 mice. Crucially, a single dose of 10-del ZIKV induced sterilizing immunity with a saturated neutralizing antibody titer, which no longer increased after challenge with an epidemic ZIKV, and completely prevented viremia. The immunized mice also developed a robust T cell response. Intracranial inoculation of 1-d-old immunocompetent CD-1 mice with 1 × 10 4 infectious focus units (IFU) of 10-del ZIKV caused no mortality, whereas infections with 10 IFU of wild-type ZIKV were lethal. Mechanistically, the attenuated virulence of 10-del ZIKV may be due to decreased viral RNA synthesis and increased sensitivity to type-1-interferon inhibition. The attenuated 10-del ZIKV was incapable of infecting mosquitoes after oral feeding of spiked-blood meals, representing an additional safety feature. Collectively, the safety and efficacy results suggest that further development of this promising, live-attenuated ZIKV vaccine candidate is warranted.
activity at 32-48 h post-transfection (Fig. 1d) . Given that the 3′UTR of flaviviruses may also modulate the host innate immune response 17, 18 , we compared the susceptibility of the WT and mutated viruses to interferon treatment. All four mutant viruses were much more sensitive than the WT virus to interferon-β inhibition, among which the mutant 10-del exhibited the greatest inhibition (Fig. 1e) . Collectively, these results suggest that 3′UTR deletions attenuate ZIKV replication through diminished viral RNA synthesis and increased vulnerability to type-1-interferon inhibition.
We tested the stability of mutant viruses by passaging them on Vero cells (an approved cell line for vaccine production 19 ). The fifth-passage (P5) viruses developed larger infectious foci (Supplementary Fig. 3a ) and faster replication kinetics than the corresponding P0 viruses on Vero cells (compare Supplementary Fig. 3b with Fig. 1c) . Complete genome sequencing of P0 and P5 viruses showed that all mutants retained the original deletions, but that the P5 viruses had accumulated additional mutations in the E-and/or NS1-encoding genes ( Supplementary Fig. 3c ), which, we hypothesize, were Vero-cell-adaptive mutation(s) and/or compensatory mutation(s) to 3′UTR deletions. Further passaging of the mutant viruses on Vero cells to P20 did not change the engineered 3′UTR deletions (data not shown), which indicates that the deletions are stable in cell culture.
We evaluated the immunogenicity and efficacy of the 3′UTR-deletion viruses in an A129 mouse model, which is deficient in interferon-α/β receptors 20 (Fig. 2a) . After subcutaneous (s.c.) inoculation with 1 × 10 4 IFU of virus, mice infected with the WT virus experienced significantly more weight loss than those infected with a mutated strain, and the four mutant-infected mice showed some, albeit statistically insignificant, weight loss when compared with the mock-infected animals ( Fig. 2b) . About 50% of the mice succumbed to the WT-virus infection, whereas no mortality was observed among mice infected with the mutated strains (Fig. 2c) . The WT virus produced significantly higher peak viremia than the mutant viruses, among which the 10-del virus had the lowest viremic profile (Fig. 2d) . The viremia for the 10-del mutant dropped to 700 IFU, 350 IFU, and undetectable levels on days 5, 6, and 7 after infection, respectively (data not shown). Sequencing analysis confirmed that the engineered deletions were retained without other de novo mutations in the mutant viruses recovered from the mouse sera (data not shown). On day 28 post-infection, mouse sera were quantified for prechallenge antibody-neutralization titers using an mCherry ZIKV (Supplementary Fig. 4 ). Comparable prechallenge neutralization titers of (1.8 ± 1.1) × 10 3 to (8.6 ± 1.5) × 10 3 dilution folds were observed among mice infected with the WT and mutant virus strains (Fig. 2e) . After challenge with 1 × 10 5 IFU of WT ZIKV (Cambodian strain FSS13025) on day 28 after immunization, the immunized mice had no detectable peripheral viremia, whereas the mock-immunized group produced a mean viremia of (8.5 ± 1.5) × 10 6 IFU/ml on day 2 after challenge ( Fig. 2f) . On day 28 after challenge, we measured the neutralization titers of the mouse sera again; notably, the postchallenge neutralization titers were equivalent to the prechallenge neutralization titers (compare Fig. 2e,g ), which suggests that a sterilizing antibody response had been achieved by a single vaccination. All together, the results demonstrate that the mutated viruses are highly attenuated, immunogenic, and protective in A129 mice.
Because the 10-del virus produced the lowest viremia in mice (Fig. 2d ), yet induced a neutralizing antibody response comparable to those of the WT and other mutants (Fig. 2e-g ), we prioritized this mutant for further characterization. At a dose of 100 IFU, 10-del-virus-infected mice showed a delayed peak viremia that was about 100-fold lower than that of the WT virus (Supplementary Fig. 5a ). Equivalent levels of prechallenge neutralizing antibody titers were induced by the WT and 10-del viruses (Supplementary Fig. 5b ), which led to complete protection from viremia after challenge with 1 × 10 6 IFU of the Puerto Rican ZIKV strain PRVABC59 ( Supplementary  Fig. 5c ). Furthermore, even when immunized at a dose of only 10 IFU, 10-del-virus-infected mice generated a neutralization titer of (9.7 ± 6.8) × 10 3 dilution folds and were fully protected from viremia after challenge (Supplementary Fig. 6 ). It is noteworthy that different doses of 10-del mutant (10-10 4 IFU) induced similar neutralization antibody titers and completely prevented viremia upon challenge, demonstrating that the 10-del virus is a potent vaccine candidate.
Given that P5 virus accumulated Vero-cell-adaptive mutations ( Supplementary Fig. 3c ), we compared the virulence and immunogenicity between the P0 and P5 10-del viruses in the A129 mice. After immunization with 100-IFU virus through the s.c. route, the P0 and P5 10-del viruses generated comparable viremia and induced equivalent neutralization titers ( Supplementary Fig. 7a,b ). After challenge with 1 × 10 6 IFU of the Puerto Rican strain PRVABC59 ZIKV through the intraperitoneal (i.p.) route, no viremia was detected in mice vaccinated with the P0 or P5 virus; by contrast, robust viremia was detected in the sham group (Supplementary Fig. 7c ). These results indicate that the Vero-cell-adaptive mutations recovered from the P5 virus do not substantially affect the virulence and immunogenicity of the 10-del virus in A129 mice.
We analyzed the T cell responses in A129 mice immunized with 1 × 10 4 IFU of WT and 10-del viruses. On day 28 postimmunization, ZIKV-specific T cells from the spleen were restimulated with live WT virus in vitro, and analyzed using an intracellular cytokine staining (ICS) assay and a Bio-Plex immunoassay. The results showed that both WT-and mutant-virus immune CD4 + and CD8 + T cells had higher interferon (IFN)-γ responses than the mock-immunized group (Fig. 3a,b) . Furthermore, total immune T cells induced more IFN-γ ( Fig. 3c) and interleukin (IL)-2 ( Fig. 3d) than those in the mock group; notably, T cells immunized with the 10-del mutant produced four-fold higher levels of IFN-γ than cells immunized with the WT virus (Fig. 3c) . These results indicate that the 10-del vaccine candidate induces a robust T cell response.
Three sets of experiments were performed to analyze the safety of the 10-del vaccine candidate. First, we measured the viral loads in different organs after s.c. inoculation of A129 mice with 1 × 10 4 On day 28 after immunization, mouse sera was measured for neutralizing titers using an mCherry ZIKV infection assay ( Supplementary Fig. 4 ). l e t t e r S IFU of WT or 10-del viruses (Fig. 4a) . On day 6 after infection, WTinfected mice had high viral loads in all organs tested, whereas the 10-del-infected mice had no virus in muscle or brain and lower viral loads in the heart, lung, liver, spleen, kidney, testes, and eye. The results suggest organ-selective attenuation of the 10-del virus. On day 10 after infection, mice infected with the WT virus retained viral loads in kidney, brain, testis, and eye, among which the testes had the highest mean titer; by contrast, no virus (≤10 2 IFU/ml) could be detected in any organs from the 10-del-infected mice. Because ZIKV infection was reported to damage the testis in mice 21, 22 , we examined the effect of immunization on the function of the testes in the A129 mice. On day 16 after immunization, similar weight and size of testes were observed in mice infected with the mock, WT, and 10-del mutant viruses (data not shown). However, total sperm counts and motile-sperm counts were reduced in mice infected with the WT virus, whereas mice infected with the 10-del virus did not have significantly compromised sperm counts (Fig. 4b) . Second, we examined the neurovirulence of the 10-del virus through intracranial (i.c.) injection of 1-d-old CD-1 mice (Fig. 4c) . The newborn mice succumbed to WT virus infection in a dose-responsive manner; even a dose of 10 IFU resulted in 25% mortality. By contrast, no mice infected with the 10-del virus died, even at a dose of 1 × 10 4 IFU. Finally, we determined whether the 10-del virus could infect Aedes aegypti mosquitoes, the main transmission vector of ZIKV in the Americas 23, 24 . After exposure to artificial-blood meals containing 1 × 10 6 IFU/ml of WT or 10-del virus, and incubation for 7 d, 56% of the engorged mosquitoes were infected by the WT virus, whereas no mosquitoes were infected by the 10-del mutant (Fig. 4d) . Furthermore, an intrathorax injection of the 10-del virus into mosquitoes did not yield any infectious virus on day 7 after injection (data not shown). Collectively, our results demonstrate that the 10-del virus had substantially reduced or absent viral loads in mouse organs, decreased neurovirulence by >1,000-fold, compared to WT virus and failed to infect the principal urban mosquito, all of which are suggestive of an excellent safety profile. A successful vaccine requires a fine balance between efficacy and safety. Live-attenuated vaccines generally offer fast and durable immunity, but sometimes, with the trade-off of reduced safety, whereas inactivated and subunit vaccines often provide enhanced safety but may require multiple doses and periodic boosters. Our data indicate that the 3′UTR-10-del ZIKV is a promising live-attenuated vaccine candidate with a good balance between efficacy and safety. A single immunization elicited robust antibody and T cell responses and induced sterilizing immunity in mice against epidemic ZIKV strain. Vaccine-induced sterilizing immunity is thought to be crucial for a ZIKV vaccine to successfully prevent viremia and congenital abnormalities. The safety profile of this vaccine candidate is highlighted by the low viremia, little and transient viral loads in organs, and limited weight loss in the immunodeficient A129 mouse model, as well as the lack of mortality among 1-d-old immunocompetent CD-1 mice after receiving an i.c. injection. In comparison, i.c. inoculation with the YFV 17D and JEV SA14-14-2 vaccines-two licensed, live-attenuated flavivirus vaccines-causes deaths in 1-d-old mice 25, 26 . Although potential homologous recombination between WT ZIKV and the 10-del-virus vaccine may pose a safety liability, it should be noted that recombination events are rare and could not be detected in cell cultures for West Nile virus (WNV) and DENV [27] [28] [29] [30] [31] . As compared to chimeric vaccines, live-attenuated ZIKV vaccines-for example, YFV 17D expressing ZIKV prM-E, or DENV expressing ZIKV prM-E 32 -our 3′UTR-mutant-virus vaccine has the advantage of retaining all ZIKV structural and nonstructural genes that might contribute to antiviral protection, as indicated by DENV studies 33, 34 . Mechanistically, the 3′UTR mutant viruses seemed to be attenuated through decreased viral RNA replication and increased sensitivity to type-1-interferon inhibition. The latter mechanism is in agreement with the observation that genetic diversity at the 3′UTR of DENV contributes to epidemic potential 18 . Future studies are needed to investigate why 20-del and 30-del mutants were less attenuated than the 10-del mutant, and how the attenuation strategy discovered in ZIKV could be applied to the development of other flavivirus vaccines. Taken together, our results indicate that the 3′UTR mutant ZIKV is an attractive vaccine candidate that should be advanced to nonhuman primates for further development.
MeTHoDS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. oNLINe MeTHoDS Cells, viruses, and antibodies. Vero cells were purchased from the American Type Culture Collection (ATCC; Bethesda, MD) and cultured at 37 °C with 5% CO 2 in a high-glucose Dulbecco modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA) with 10% FBS (FBS; HyClone Laboratories, Logan, UT) and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA). The following antibodies were used: a mouse monoclonal antibody (mAb) 4G2 that is cross-reactive with flavivirus E protein (ATCC), ZIKV-specific HMAF (hyperimmune ascitic fluid; obtained from the World Reference Center of Emerging Viruses and Arboviruses (WRCEVA) at the University of Texas Medical Branch), antimouse IgG antibody labeled with horseradish peroxidase (KPL, Gaithersburg, MD), and goat anti-mouse IgG conjugated with AlexaFluor 488 (Thermo Fisher Scientific). The ZIKV Cambodian strain FSS13025 (GenBank number KU955593.1) was produced from an infectious cDNA clone pFLZIKV 12 . The Puerto Rican strain PRVABC59 (GenBank number KU501215) was obtained from WRCEVA. All cell lines tested negative for mycoplasma. Antibody 4G2, ZIKV-specific HMAF, anti-mouse IgG, and goat anti-mouse IgG conjugated with AlexaFluor 488 were diluted 1:40, 1:2,000, 1:2,000 and 1:1,000 folds, respectively, in the indicated assays.
Plasmid construction. To engineer 3′UTR deletions, overlap PCR containing the deletions was performed to amplify the DNA fragment between unique restriction-enzyme sites EcoRI and ClaI. The DNA fragments containing the 3′UTR deletions were individually introduced into the pFLZIKV and pZIKV Rep (replicon cDNA plasmid 16 ) through the EcoRI and ClaI sites. The construction of the cDNA clone for mCherry ZIKV will be reported elsewhere. DNA sequencing was performed to verify all the constructs. All restriction enzymes were purchased from New England BioLabs (Ipswitch, MA). Primer sequences are available upon request.
RNA transcription and transfection. Genomic ZIKV, mCherry ZIKV, and replicon RNAs were transcribed in vitro using a T7 mMessage mMachine kit (Ambion, Austin, TX) from corresponding cDNA plasmids prelinearized by restriction enzyme ClaI. The RNA was precipitated with lithium chloride, washed with 70% ethanol, resuspended in RNase-free water, quantitated by spectrophotometry, and stored at −80 °C in aliquots. The RNA transcripts (10 µg) were electroporated into Vero cells following a protocol described previously 35 .
Indirect immunofluorescence assays (IFA).
After transfection with genomic RNA, Vero cells were grown in an eight-well Lab-Tek chamber slide (Thermo Fisher Scientific, Waltham, MA). At the indicated time points, the transfected cells were fixed in 100% methanol at −20 °C for 15 min. After 1 h of incubation in a blocking buffer (containing 1% FBS and 0.05% Tween-20 in PBS), the cells were treated with a mouse monoclonal antibody 4G2 for 1 h and washed three times with PBS (5 min for each wash). The cells were further incubated with a goat anti-mouse IgG conjugated with AlexaFluor 488 for 1 h in blocking buffer, after which the cells were washed three times with PBS. The slides were mounted in a mounting medium with DAPI (4′, 6-diamidino-2-phenylindole; Vector Laboratories) and analyzed under a fluorescence microscope equipped with a video-documentation system (Olympus).
Luciferase assay. The luciferase assay was performed as previously reported 16 . Briefly, Vero cells were transfected with 10 µg of WT or mutant ZIKV replicon RNAs and seeded in a 12-well plate. At the indicated time points, the cells were washed once with PBS and lysed using cell-lysis buffer (Promega, Madison, WI). The lysed cells were scraped from plates and stored at −80 °C. The luciferase signals were quantified by Cytation 5 (Biotek) following the manufacturer's instructions.
Stability of 3′UTR mutants, RNA extraction, and RT-PCR. To examine the stability of 3′UTR mutants, we passaged the viruses on Vero cells for twenty rounds. T-25 flasks were seeded with 1.5 × 10 6 Vero cells per flask. The viruses derived from RNA transfection, defined as P0, were used to infect the Vero cells. At 5 d p.i., 100 µl of culture fluid was transferred to a new T-25 flask containing naive Vero cells in 5 ml of culture medium. After five rounds or twenty rounds of such passaging (P5 and P20), QIAamp Viral RNA Kit (Qiagen) was used to extract viral RNAs from the culture fluids. SuperScript III one-step RT-PCR kits (Invitrogen) was used to amplify viral RNAs. The RT-PCR products were subjected to DNA sequencing. Three independent passages were performed for each mutant virus.
Immunostaining focus assay and immunostaining. An immunostaining focus assay was performed by serial tenfold dilutions (10 1 -10 6 ) of viral samples in DMEM. For each dilution, 100 µl of sample was added to a 24-well plate containing 90% confluent Vero cells. The infected cells were swirled every 15 min to ensure complete coverage of the cell monolayer for even infection. After 1 h incubation, we added into each well 0.5 ml of methyl cellulose overlay containing 2% FBS 1% penicillin/streptomycin. The plate was incubated at 37 °C for 4 d, after which the methyl cellulose overlay was removed, 0.5 ml methanol-acetone (1:1) fixation solution was added per well, and the plate was incubated for 15 min at room temperature. After removing the fixation solution, the plates were air dried, washed three times with PBS, incubated in buffer (PBS with 3% FBS) for 1 h, and reacted with ZIKV-specific HMAF for 1 h. The plates were washed three times with PBS, incubated for 1 h with the horseradish peroxidase-conjugated secondary antibody (KPL, Gaithersburg, MD), and detected for immunofocusing through the addition of aminoethylcarbazole substrate, following the manufacturer's instructions (ENZO Life sciences, Farmingdale, MA).
Viral-replication analysis. Vero cells in 12-well plates (80% confluent) were infected with either P0 or P5 ZIKV at an MOI of 0.01 in duplicate wells. Viral stocks were diluted to appropriate concentrations in DMEM containing 2% FBS and 1% penicillin/streptomycin and added to infect cells (100 µl of virus per well). The inoculants were removed after 1 h infection at 37 °C. The cell monolayers were washed three times with PBS, and 1 ml DMEM medium containing 2% FBS and 1% penicillin/streptomycin was added to each well. The medium was collected daily for immunostaining focus assay as described above.
Vaccination and challenge of mice. All animal experiments were approved by the University of Texas Medical Branch IACUC. A129 mice were obtained from colonies maintained under specific pathogen-free conditions at University of Texas Medical Branch. 3-week-old A129 mice were infected with 1 × 10 4 IFU, 1 × 10 2 IFU, or 10 IFU WT or mutant viruses through the s.c. route. PBS was given to the mock-infected mice through the same route. Disease progression of mice was monitored by weight loss and deaths. To measure viremia, mice were anesthetized and bled through the retro-orbital sinus (r.o.) every other day. On day 28 p.i., mice were measured for neutralizing antibody titers using an mCherry ZIKV infection assay. The immunized mice were then challenged through the i.p. route with either 1 × 10 5 IFU of FSS13025 or 1 × 10 6 IFU of PRVABC59 ZIKV, and measured for viremia on day 2 after challenge. Serum was collected by centrifuging the blood at 3,380g for 5 min and stored it at −80 °C. Viral titers were determined by an immunostaining focus assay on Vero cells, as described above.
Neurovirulence on newborn CD-1 mice. Groups of 1-d-old outbred CD-1 mice (n = 7-10; Charles River Laboratories) were injected i.c. with WT or 10-del with serial tenfold dilutions from 10,000 IFU to 10 IFU. Mice were monitored daily for morbidity and mortality.
Organ virus titers. A129 mouse organs were removed and measured for viral loads on days 6 and 10 p.i. after vaccination with 1 × 10 4 IFU of WT and del-10 virus through the s.c. route, as previously described 20 .
Testis and sperm-count analyses. A129 mice were infected with 1 × 10 4 IFU of WT or 10-del mutant virus. A mock-infected group with PBS was included as a negative control. On day 16 p.i., the mice were euthanized and necropsied. Epididymis and testes were removed immediately, as previously described 36 . Briefly, the epididymis was placed into 1 ml of prewarmed M2 media at 37 °C. To release the sperm, we cut the epididymis lengthwise six times and incubated the mixture at 37 °C for 10 min with agitation every 2 min. After the incubation,
